Lactoperoxidase-mediated degradation of single-walled carbon nanotubes in the presence of pulmonary surfactant

Carbon nanotubes (CNTs) may elicit inflammatory responses following pulmonary exposure. Conversely, enzymatic biodegradation of CNTs by inflammatory cells has also been reported. The aim of this study was to study the degradation of oxidized single-walled CNTs (ox-SWCNTs) by lactoperoxidase (LPO), a secreted peroxidase present in the airways, and whether pulmonary surfactant affects this biodegradation. To this end, ox-SWCNTs were incubated in vitro with recombinant bovine LPO + H₂O₂ + NaSCN in the presence and absence of porcine lung surfactant (Curosurf®) and biodegradation was monitored using UV–Vis–NIR spectroscopy, Raman spectroscopy, and scanning electron microscopy. The interaction of recombinant LPO with bundles of ox-SWCNTs was confirmed by atomic force microscopy. Cell-free biodegradation of ox-SWCNTs was also observed ex vivo in murine bronchoalveolar lavage fluid in the presence of H₂O₂ + NaSCN. Our study provides evidence for biodegradation of ox-SWCNTs with a lung surfactant ‘bio-corona’ and expands the repertoire of mammalian peroxidases capable of biodegradation of ox-SWCNTs. These findings are relevant to inhalation exposure to these materials, as LPO serves as an important component of the airway defense system.     

Differential phenotype of immune cells in blood and milk following pegylated granulocyte colony-stimulating factor therapy during a chronic Staphylococcus aureus infection in lactating Holsteins

Neutrophils are principal host innate immune cell responders to mastitis infections. Thus, therapies have been developed that target neutrophil expansion. This includes the neutrophil-stimulating cytokine granulocyte colony-stimulating factor (gCSF). Pegylated gCSF (PEG-gCSF; Imrestor, Elanco Animal Health, Greenfield, IN) has been shown to reduce the natural incidence of mastitis in periparturient cows in commercial settings and reduce severity of disease against experimental mastitis challenge. Pegylated gCSF stimulates neutrophil expansion but also induces changes in monocyte and lymphocyte circulating numbers, surface protein expression changes, or both. We hypothesized that PEG-gCSF modulates surface expression of monocytes and neutrophils and facilitates their migration to the mammary gland. We challenged 8 mid-lactation Holsteins with approximately 150 cfu of Staphylococcus aureus (Newbould 305) in a single quarter via intramammary infusion. All animals developed chronic infections as assessed by bacteria counts and somatic cell counts (SCC). Ten to 16 wk postchallenge, 4 of the animals were treated with 2 subcutaneous injections of PEG-gCSF 7 d apart. Complete blood counts, SCC, bacterial counts, milk yield, feed intake, neutrophils extracellular trap analysis, and flow cytometric analyses of milk and blood samples were performed at indicated time points for 14 d after the first PEG-gCSF injection. The PEG-gCSF-treated cows had significantly increased numbers of blood neutrophils and lymphocytes compared with control cows. Flow cytometric analyses revealed increased surface expression of myeloperoxidase (MPO) on neutrophils and macrophages in milk but not in blood of treated cows. Neutrophils isolated from blood of PEG-gCSF-treated cows had decreased surface expression of CD62L (L-selectin) in blood, consistent with cell activation. Surprisingly, CD62L cell surface expression was increased on neutrophils and macrophages sourced from milk from treated animals compared with cells isolated from controls. The PEG-gCSF-treated cows did not clear the S. aureus infection, nor did they significantly differ in SCC from controls. These findings provide evidence that PEG-gCSF therapy modifies cell surface expression of neutrophils and monocytes. However, although surface MPO⁺ cells accumulate in the mammary gland, the lack of bacterial control from these milk-derived cells suggests an incomplete role for PEG-gCSF treatment against chronic S. aureus infection and possibly chronic mammary infections in general.     

Plasma myeloperoxidase,NT‐proBNP,and troponin‐I in patients on CAPD compared with those on regular hemodialysis

Myeloperoxidase (MPO) is a hemoprotein that is released during inflammation and may lead to irreversible protein and lipid modification, increasing levels of oxidized low density lipoprotein, and promoting athrogenesis. Recently, it has been considered as a risk factor for cardiovascular diseases. Similarly, the measurement of carotid intima‐media thickness gives an indication about the degree of atherosclerosis and prediction of clinical cardiovascular events. Elevated white blood cells counts may indicate a state of acute inflammation and follow its progression. Dialysis patients are at a high risk of developing cardiovascular disease compared with healthy subjects. The role of N‐terminal pro‐brain natriuretic peptide and increased cardiac troponin in identification and prognostication of cardiovascular diseases in end‐stage renal disease patients has been investigated. The current study aimed to evaluate plasma MPO and its possible relationship with carotid intima‐media thickness, troponin I, N‐terminal pro‐brain natriuretic peptide (NT‐proBNP), and insulin resistance as measured by homeostatic model assessment (HOMA index) in a cohort of Saudi patients who are undergoing hemodialysis (HD) vs. continuous ambulatory peritoneal dialysis for end‐stage renal disease. Plasma MPO was significantly higher in patients on continuous ambulatory peritoneal dialysis (CAPD) than in those on HD and in normal subjects (P<0.001). Conversely, NT‐proBNP plasma levels were significantly higher in patients on HD (both predialysis and postdialysis) than in those on CAPD (P<0.01) and than normal subjects. Similarly, plasma troponin‐I levels were significantly higher in patients on HD compared with those of CAPD and than normal subjects (P<0.001). Plasma troponin‐I and NT‐proBNP levels were positively correlated in the 3 groups namely those on CAPD, Pre‐HD, and post‐HD (r: 0.464 and P=0.047; r: 0.330 and P=0.013; and r: 0.452 and P=0.024), respectively. There was no correlation between the MPO level and carotid intima‐media thickness (P>0.05). However, plasma MPO level correlated positively with the white blood cell count in patients on CAPD and in those on HD (P<0.05). Our findings suggest an increased oxidative stress in CAPD patients compared with HD patients, while the reported difference in plasma NT‐proBNP and troponin‐I may be related to the rapid decline of residual renal function in HD and type of membrane used in the HD dialysis procedure itself.     

谷维素抑制DSS诱导的小鼠结肠炎症及其分子机理研究

谷维素(oryzanol)是米糠中重要的活性物质之一。C57BL/6小鼠连续饮用1.0%葡聚糖硫酸钠(dextran sulphate sodium,DSS)12 d,用以建立溃疡性结肠炎模型,评估谷维素的抗炎作用及其分子机理研究。结果发现:谷维素组小鼠能明显缓解DSS诱导的结肠炎症,小鼠肠壁厚度、结肠长度、结肠重量、炎症细胞浸润、疾病活动指数(disease active index,DAI)等病理指标明显改变;谷维素也能明显改善结肠组织中炎症损伤重要生化指标如髓过氧化物酶(myeloperoxidase,MPO)和丙二醛(malondialdehyde,MDA)的含量,同时减少血浆中亚硝酸盐的含量;RT-q PCR技术分析发现结肠组织炎症因子TNF-α、IFN-γ、IL-1和IL-6等m RNA表达水平受到明显抑制,Western blotting分析进一步证实了谷维素能抑制炎症因子的蛋白表达水平。结论:谷维素对DSS诱导的小鼠结肠炎具有抑制作用,其作用的分子机理可能与下调炎症因子的表达相关。     

高效液相色谱-氢化物发生原子荧光光谱法测定食品中多形态硒含量

目的 探究急性心肌梗死(AMI)患者经皮冠状动脉介入术(PCI)后血清成纤维细胞生长因子21(FGF-21)、髓过氧化物酶(MPO)水平与预后的关系。方法 选择2016年1月至2018年12月在我院接受PCI术治疗的108例AMI患者作为研究对象。根据随访过程中是否发生主要不良心血管事件(MACE),病人分为预后不良组(25例)和预后良好组(83例)。采用酶联免疫吸附法检测受试者血清FGF-21水平,采用胶体金免疫层析法检测受试者血清MPO水平。分析FGF-21、MPO与AMI患者PCI术后MACE发生的关系及诊断MACE发生的效能。结果 预后不良组血清FGF-21、MPO水平均高于预后良好组,差异均有统计学意义(P＜0.05)。FGF-21＋MPO诊断AMI患者PCI术后MACE发生的ROC曲线下面积(AUC)为0.860,高于FGF-21、MPO单独诊断AMI患者PCI术后MACE发生的AUC。FGF-21＞140.41 ng/L和FGF-21≤140.41 ng/L的患者,MACE发生率分别为39.58%和10.00%,差异有统计学意义(P＜0.001)。MPO＞419.42 μg/L和MPO≤419.42 μg/L的患者,MACE发生率分别为35.00%和8.33%,差异有统计学意义(P＝0.001)。Cox单因素及Cox多因素分析显示FGF-21、MPO与AMI患者PCI术后MACE发生密切相关(均P＜0.05)。结论 AMI患者PCI术后血清FGF-21、MPO水平与预后有关。高水平的FGF-21、MPO与MACE发生密切相关。     

Synthetic Guaiacol Derivatives as Promising Myeloperoxidase Inhibitors Targeting Atherosclerotic Cardiovascular Disease

Myeloperoxidase (MPO) is known to cause oxidative stress and inflammation leading to cardiovascular disease (CVD) complications. MPO-mediated oxidation of lipoproteins leads to dysfunctional entities altering the landscape of lipoprotein functionality. The specificity of guaiacol derivatives toward preventing MPO-mediated oxidation to limit MPO's harmful effects is unknown. Diligent in silico studies were accomplished for a portfolio of compounds with guaiacol as a building block. The compounds’ activity toward MPO inhibition was also validated. The role of these chemical entities in controlling MPO-mediated oxidation of lipoproteins (LDL and HDL) was shown to agree with our approach of developing powerful MPO inhibitors. The mechanism of MPO inhibition was demonstrated to be reversible in nature. This study reveals that there is great potential for guaiacol derivatives as therapeutics for CVD by modulating lipid profiles, reducing atherosclerotic plaque burden, and subsequently optimizing cardiovascular functions.     

Degradation of fullerene C60 by human myeloperoxidase and some reaction products

Abstract

The biodegradation of the fullerene molecule C₆₀ under the action of the human myeloperoxidase enzyme accompanied by a complete loss of the topology of the fullerene core. Analysis of this reaction mixture using UV and FTIR spectroscopy, chromatographic and mass spectrometry methods showed that the degradation proceeds without the formation of significant amounts of hydroxylated compounds. Among other intermediate compounds aromatic compounds were detected.     

蕲蛇酶减轻大鼠局灶性脑缺血再灌注损伤的实验研究

目的:探讨蕲蛇酶(acutobin) 在局灶性脑缺血再灌注损伤模型中的保护作用及其机制。方法:线栓法制备大鼠大脑中动脉闭塞(MCAO) 模型, 缺血3 h 后恢复血流再灌24 h 。观察蕲蛇酶对脑梗死面积、脑组织中髓过氧化物酶(MPO)、诱导型一氧化氮合酶(iNOS) 活性、一氧化氮(NO)、丙二醛(MDA) 含量和超氧化物歧化酶(SOD) 活性的影响。结果:蕲蛇酶能有效减小脑梗死灶, 缓解MPO 升高、降低MDA 含量、抑制iNOS 活性, 降低NO 含量。结论:蕲蛇酶对脑缺血再灌注损伤有保护作用, 其机制可能与缓解MPO 升高以及抑制脑组织中iNOS 活性, 降低NO、MDA 含量有关。     

Effects of enoxaparin on myeloperoxidase release during hemodialysis

Myeloperoxidase (MPO) is a proteolytic and prooxidant enzyme largely assembled with the vascular wall, and a heparin‐binding protein. We studied if low‐molecular‐weight heparin enoxaparin administered for hemodialysis (HD) anticoagulation causes systemic MPO activation. Plasma MPO levels were measured in patients undergoing maintenance HD with an intravenous bolus of enoxaparin. Patients were retested during HD employing dialyzers with heparin‐grafted polyacrylonitrile membrane and no systemic enoxaparin administration. During enoxaparin‐anticoagulated HD plasma MPO levels strikingly increased in all patients (8.6‐fold at 10 minutes and 3.3‐fold at 120 minutes, both P < 0.0001). The increments were directly associated with the enoxaparin dosage and strongly inversely with the predialysis levels of the enzyme. The increase in plasma MPO during systemic heparin‐free HD was significantly less pronounced. Enoxaparin administered for HD anticoagulation induces a marked and dose‐dependent increase in plasma MPO as a plausibly favorable result of the liberation of the enzyme from the vascular wall.